Epidemiology of Clostridioides difficile infection in hospitalized patients in Spain: An eight-year review (2012-2019).

Clostridioides difficile infection Community-associated infection Epidemiology Epidemiología Factores de riesgo de vacunación Healthcare-associated infection Infección asociada a la comunidad Infección por Clostridioides difficile Infección relacionada con la asistencia sanitaria Vaccination CDI risk factors

Journal

Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 30 12 2020
accepted: 07 04 2021
entrez: 7 3 2022
pubmed: 8 3 2022
medline: 11 3 2022
Statut: ppublish

Résumé

Clostridioides difficile infection (CDI) is a disease that is potentially preventable by vaccination. A good knowledge of its epidemiology, which can change over time, is warranted for prevention purposes and to help decision-making on the use of vaccines in public health programs. The objective of the research was to determine the epidemiology of healthcare-associated CDI (HA-CDI) and community-associated CDI (CA-CDI) in hospitalized patients in Spain using point prevalence data. Point prevalence survey data on infections of hospitalized patients for years 2012-2019 were analyzed. HA-CDI and CA-CDI prevalence rates were calculated. Both HA-CDI and CA-CDI, as well as age group prevalence rates, were examined for trends. Patient comorbidities were tested for association to CDI. The prevalence of CDI in Spanish hospitals has grown exponentially from 14.1% in 2012 to 35.9% in 2019 (cases/10.000 hospitalized patients). Almost two thirds of the cases are of nosocomial onset. This increase was observed for HA-CDI and CA-CDI at an annual rate of 1.11% (CI 95% 1.08-1.15) and 1.09% (CI 95% 1.04-1.13), respectively. Patients 50 years old or older represent 87% of the total number of cases. Patients suffering from neoplasm (OR 1.39), immunodeficiency (OR 3.26), neutropenia (OR 3.70), cirrhosis (OR 1.92) and chronic renal failure (OR 1.91) have a significant increased risk of developing CDI, after adjusting for age. In Spain, the prevalence rate of both HA-CDI and CA-CDI have been increasing. Burden of CDI as well as clinical and epidemiological characteristics of CDI patients will help to support public health decision-making.

Sections du résumé

BACKGROUND BACKGROUND
Clostridioides difficile infection (CDI) is a disease that is potentially preventable by vaccination. A good knowledge of its epidemiology, which can change over time, is warranted for prevention purposes and to help decision-making on the use of vaccines in public health programs. The objective of the research was to determine the epidemiology of healthcare-associated CDI (HA-CDI) and community-associated CDI (CA-CDI) in hospitalized patients in Spain using point prevalence data.
METHODS METHODS
Point prevalence survey data on infections of hospitalized patients for years 2012-2019 were analyzed. HA-CDI and CA-CDI prevalence rates were calculated. Both HA-CDI and CA-CDI, as well as age group prevalence rates, were examined for trends. Patient comorbidities were tested for association to CDI.
RESULTS RESULTS
The prevalence of CDI in Spanish hospitals has grown exponentially from 14.1% in 2012 to 35.9% in 2019 (cases/10.000 hospitalized patients). Almost two thirds of the cases are of nosocomial onset. This increase was observed for HA-CDI and CA-CDI at an annual rate of 1.11% (CI 95% 1.08-1.15) and 1.09% (CI 95% 1.04-1.13), respectively. Patients 50 years old or older represent 87% of the total number of cases. Patients suffering from neoplasm (OR 1.39), immunodeficiency (OR 3.26), neutropenia (OR 3.70), cirrhosis (OR 1.92) and chronic renal failure (OR 1.91) have a significant increased risk of developing CDI, after adjusting for age.
CONCLUSION CONCLUSIONS
In Spain, the prevalence rate of both HA-CDI and CA-CDI have been increasing. Burden of CDI as well as clinical and epidemiological characteristics of CDI patients will help to support public health decision-making.

Identifiants

pubmed: 35249672
pii: S2529-993X(22)00024-7
doi: 10.1016/j.eimce.2021.04.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-130

Informations de copyright

Copyright © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Ángel Asensio (Á)

Preventive Medicine Department, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain. Electronic address: angasenve@gmail.com.

Alberto Vallejo-Plaza (A)

Preventive Medicine Department, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.

Lina M Parra (LM)

Preventive Medicine Department, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.

Rafael Ortí-Lucas (R)

Preventive Medicine Department, University Clinical Hospital of Valencia, Valencia, Spain.

Inmaculada Salcedo (I)

Preventive Medicine Department, Reina Sofia Hospital, Cordoba, Spain.

Antonio Ramos (A)

Internal Medicine Department, Infectious Disease Unit, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.

Mireia Cantero (M)

Preventive Medicine Department, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Sociedad Española de Medicina Preventiva, Salud Pública e Higiene, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH